| Dr Stephen Benjamin Moses, MD | |
|
3300 Gallows Rd, Falls Church, VA 22042 | |
| (703) 776-4002 | |
| Not Available |
| Full Name | Dr Stephen Benjamin Moses |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Location | 3300 Gallows Rd, Falls Church, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801052170 | NPI | - | NPPES |
| 254718 | Other | MD | JHHC |
| 043755701 | Medicaid | MD | |
| Y1220011 | Other | MD | CAREFIRST |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 0101251733 (Virginia) | Primary |
| Entity Name | Childrens Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912939703 PECOS PAC ID: 0244143170 Enrollment ID: O20031107000130 |
News Archive
New clinical strains of cholera appear to have evolved a distinctly different mechanism to cause the same disease according to research published in the current issue of the online journal mBio-.
Researchers at the University of East Anglia have shown that a prostate cancer urine test can identify men at 'intermediate risk' who can safely avoid immediate treatment and benefit from 'active surveillance' instead.
Younger patients with colorectal cancer that has spread (metastasised) to other parts of the body represent a high-risk group that is less likely to respond to anti-cancer treatments.
Emergent BioSolutions Inc. today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP™) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with Abbott.
Nearly of 300 of the world's leading researchers focused on the problem of prostate cancer will begin a three-day meeting today to discuss the latest scientific data and breakthroughs in prostate cancer. The meeting, held in Incline Village at Lake Tahoe in Nevada, is the 16th Scientific Retreat sponsored by the Prostate Cancer Foundation (PCF).
› Verified 1 days ago
| Entity Name | Inova Health Care Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952320061 PECOS PAC ID: 2466351093 Enrollment ID: O20040102000644 |
News Archive
New clinical strains of cholera appear to have evolved a distinctly different mechanism to cause the same disease according to research published in the current issue of the online journal mBio-.
Researchers at the University of East Anglia have shown that a prostate cancer urine test can identify men at 'intermediate risk' who can safely avoid immediate treatment and benefit from 'active surveillance' instead.
Younger patients with colorectal cancer that has spread (metastasised) to other parts of the body represent a high-risk group that is less likely to respond to anti-cancer treatments.
Emergent BioSolutions Inc. today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP™) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with Abbott.
Nearly of 300 of the world's leading researchers focused on the problem of prostate cancer will begin a three-day meeting today to discuss the latest scientific data and breakthroughs in prostate cancer. The meeting, held in Incline Village at Lake Tahoe in Nevada, is the 16th Scientific Retreat sponsored by the Prostate Cancer Foundation (PCF).
› Verified 1 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952461816 PECOS PAC ID: 3779495858 Enrollment ID: O20040105000308 |
News Archive
New clinical strains of cholera appear to have evolved a distinctly different mechanism to cause the same disease according to research published in the current issue of the online journal mBio-.
Researchers at the University of East Anglia have shown that a prostate cancer urine test can identify men at 'intermediate risk' who can safely avoid immediate treatment and benefit from 'active surveillance' instead.
Younger patients with colorectal cancer that has spread (metastasised) to other parts of the body represent a high-risk group that is less likely to respond to anti-cancer treatments.
Emergent BioSolutions Inc. today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP™) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with Abbott.
Nearly of 300 of the world's leading researchers focused on the problem of prostate cancer will begin a three-day meeting today to discuss the latest scientific data and breakthroughs in prostate cancer. The meeting, held in Incline Village at Lake Tahoe in Nevada, is the 16th Scientific Retreat sponsored by the Prostate Cancer Foundation (PCF).
› Verified 1 days ago
| Entity Name | Emergency Medicine Associates Pa Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134117393 PECOS PAC ID: 8022914522 Enrollment ID: O20070919000389 |
News Archive
New clinical strains of cholera appear to have evolved a distinctly different mechanism to cause the same disease according to research published in the current issue of the online journal mBio-.
Researchers at the University of East Anglia have shown that a prostate cancer urine test can identify men at 'intermediate risk' who can safely avoid immediate treatment and benefit from 'active surveillance' instead.
Younger patients with colorectal cancer that has spread (metastasised) to other parts of the body represent a high-risk group that is less likely to respond to anti-cancer treatments.
Emergent BioSolutions Inc. today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP™) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with Abbott.
Nearly of 300 of the world's leading researchers focused on the problem of prostate cancer will begin a three-day meeting today to discuss the latest scientific data and breakthroughs in prostate cancer. The meeting, held in Incline Village at Lake Tahoe in Nevada, is the 16th Scientific Retreat sponsored by the Prostate Cancer Foundation (PCF).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stephen Benjamin Moses, MD 3300 Gallows Rd, Falls Church, VA 22042-3307 Ph: (703) 776-4002 | Dr Stephen Benjamin Moses, MD 3300 Gallows Rd, Falls Church, VA 22042 Ph: (703) 776-4002 |
News Archive
New clinical strains of cholera appear to have evolved a distinctly different mechanism to cause the same disease according to research published in the current issue of the online journal mBio-.
Researchers at the University of East Anglia have shown that a prostate cancer urine test can identify men at 'intermediate risk' who can safely avoid immediate treatment and benefit from 'active surveillance' instead.
Younger patients with colorectal cancer that has spread (metastasised) to other parts of the body represent a high-risk group that is less likely to respond to anti-cancer treatments.
Emergent BioSolutions Inc. today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP™) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with Abbott.
Nearly of 300 of the world's leading researchers focused on the problem of prostate cancer will begin a three-day meeting today to discuss the latest scientific data and breakthroughs in prostate cancer. The meeting, held in Incline Village at Lake Tahoe in Nevada, is the 16th Scientific Retreat sponsored by the Prostate Cancer Foundation (PCF).
› Verified 1 days ago
Rumaisa Hameed, M.D Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3300 Gallows Rd, Falls Church, VA 22042 Phone: 703-776-3582 | |
Dr. Temitayo Akinsode Ogundipe, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3300 Gallows Rd, Falls Church, VA 22042 Phone: 703-776-4001 Fax: 703-776-7113 | |
Dr. Somashekar N Rao, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 3300 Gallows Road, Falls Church, VA 22042 Phone: 703-776-2052 | |
Mrs. Swapna Adi Reddy, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3300 Gallows Rd, Falls Church, VA 22042 Phone: 703-822-3008 | |
Dr. Brigid C Gray, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3300 Gallows Rd, Department Of Medicine, Falls Church, VA 22042 Phone: 703-776-3582 | |
Tejasri Chandrabhatla, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3300 Gallows Rd, Falls Church, VA 22042 Phone: 703-776-4001 Fax: 703-776-7113 | |
Dr. Alita Mishra, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3300 Gallows Rd, Physician Billing, Falls Church, VA 22042 Phone: 703-776-1110 Fax: 703-776-2917 |